New Data from AbbVie’s Phase IIb Aviator Trial Demonstrate High Sustained Viral Response Rates Across Multiple Patient Types with HCV Genotype 1

Nyheten uppdaterades 2013-04-23 16:07

AMSTERDAM, Apr. 23, 2013 (NYSE: ABBV)  – Results from “Aviator,”  AbbVie’s phase IIb clinical trial of its investigational direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection, continue to demonstrate high sustained viral response (SVR) rates against genotype 1 HCV, across patient types. Data show greater than 90 percent SVR were achieved in patients new to treatment…

Källa: Mynewsdesk news release

Lämna gärna en kommentar